Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Diabetes Drug Canagliflozin Receives Boxed Warning for Amputation Risk

By Joanne Van Zuidam | May 18, 2017

In May 2016 the U.S. Food and Drug Administration (FDA) issued an alert after interim results from two trials suggested that canaglifllozin (Invokana) carried an increased risk of amputation.

Now, the FDA has concluded that the type 2 diabetes drug canagliflozin, manufactured by Johnson & Johnson, causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including its most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.

Canagliflozin is also prescribed in combination with the diabetes medicine metformin under the brand names Invokamet and Invokamet XR. The warning applies to those drugs as well.

Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor and lowers blood sugar by causing the kidneys to remove sugar from the body through the urine. SGLT2s are prescribed along with diet exercise to lower blood sugar in adults with type 2 diabetes.

The decision was based on final results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus). In both trials, leg and foot amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo.

Each study lasted a year with a combined 6,000 patients receiving canagliflozin. The CANVAS trial showed that the risk of amputation for patients in the trial was equivalent to 5.9 out of every 1,000 patients treated with canagliflozin compared to 2.8 out of every 1,000 patients treated with placebo.

In the CANVAS-R trial, the risk of amputation for patients in the trial was equivalent to 7.5 out of every 1,000 patients treated with canagliflozin compared to 4.2 out of every 1,000 patients treated with placebo over the same time span.

Amputations of the toe and middle of the foot were the most common, according to the FDA’s announcement. However, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.

The FDA warns health care professionals to consider factors that may predispose patients to the need for amputations before prescribing canagliflozin. These factors include a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers.

Any patients already receiving canagliflozin should be monitored for the signs and symptoms such as developing new pain or tenderness, sores or ulcers, or infections in your legs or feet. If these complications occur, canagliflozin should be discontinued.

 

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE